Zhang Yunjing, Wang Shiwen, Chen Yukun, Zhang Junqian, Yang Jing, Xian Jingrong, Li Lihui, Zhao Hu, Hoffman Robert M, Zhang Yanmei, Jia Lijun
Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Department of Laboratory Medicine, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
Front Oncol. 2021 Jun 14;11:666549. doi: 10.3389/fonc.2021.666549. eCollection 2021.
Esophageal squamous cell carcinoma (ESCC) is a recalcitrant cancer. The Chinese herbal monomer fangchinoline (FCL) has been reported to have anti-tumor activity in several human cancer cell types. However, the therapeutic efficacy and underlying mechanism on ESCC remain to be elucidated. In the present study, for the first time, we demonstrated that FCL significantly suppressed the growth of ESCC both and . Mechanistic studies revealed that FCL-induced G1 phase cell-cycle arrest in ESCC which is dependent on p21 and p27. Moreover, we found that FCL coordinatively triggered Noxa-dependent intrinsic apoptosis and DR5-dependent extrinsic apoptosis by transactivating ATF4, which is a novel mechanism. Our findings elucidated the tumor-suppressive efficacy and mechanisms of FCL and demonstrated FCL is a potential anti-ESCC agent.
食管鳞状细胞癌(ESCC)是一种难治性癌症。据报道,中药单体粉防己碱(FCL)在几种人类癌细胞类型中具有抗肿瘤活性。然而,FCL对ESCC的治疗效果及其潜在机制仍有待阐明。在本研究中,我们首次证明FCL在体内和体外均能显著抑制ESCC的生长。机制研究表明,FCL诱导ESCC细胞G1期细胞周期阻滞,这依赖于p21和p27。此外,我们发现FCL通过反式激活ATF4协同触发Noxa依赖的内源性凋亡和DR5依赖的外源性凋亡,这是一种新机制。我们的研究结果阐明了FCL的肿瘤抑制作用及其机制,并证明FCL是一种潜在的抗ESCC药物。